(Reuters) – Two House Committees have requested data and documents from the Food and Drug Administration related to the agency’s accelerated approval of Biogen Inc’s recently approved Alzheimer’s drug Aduhelm, Stat News reported, citing a letter by the committees.
(Reporting by Manas Mishra in Bengaluru)
